نتائج البحث

CD38 symmetric dimethyl site R58 promotes malignant tumor cell immune escape by regulating the cAMP-GSK3β-PD-L1 axis

• Authors : Lin Liang; Chunxue Yue; Wentao Li

Subjects: CD38; PD-L1; Tumor immunotherapy

• Source: Heliyon, Vol 10, Iss 19, Pp e37958- (2024)

تفاصيل العنوان

Research progress and challenges of the PD-1/PD-L1 axis in gliomas.

• Authors : Jiacheng, Dong¹ (AUTHOR); Jiayue, Cui² (AUTHOR); Ying, Guo² (AUTHOR)

Subjects: *PROGRAMMED cell death 1 receptors; *PROGRAMMED death-ligand 1; *GLIOMAS

• Source: Cell & Bioscience. 9/27/2024, Vol. 14 Issue 1, p1-13. 13p.

تفاصيل العنوان

Artificial intelligence in studies related to programmed cell death protein PD-L1 in non-small cell lung cancer.

• Authors : Huseynli, Sanan¹; Jafarlı, Leyla¹; Shikhaliyeva, Gulara¹

• Source: Gulhane Medical Journal. 2024 Suppl, Vol. 66, p12-12. 1/2p.

تفاصيل العنوان

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.

• Authors : Liu, Qiang; Guan, Yujing; Li, Shenglong

Subjects: PROGRAMMED death-ligand 1; PROGRAMMED cell death 1 receptors; RENAL cell carcinoma

• Source: Molecular Cancer; 9/2/2024, Vol. 23 Issue 1, p1-26, 26p

تفاصيل العنوان

LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer.

• Authors : Wu, Bo; Huang, Xin; Shi, Xiang

Subjects: NON-small-cell lung carcinoma; IMMUNE checkpoint proteins; TREATMENT effectiveness

• Source: Molecular Cancer; 9/2/2024, Vol. 23 Issue 1, p1-16, 16p

تفاصيل العنوان

RNF26 up-regulates PD-L1 to regulate the cancer immune response in ccRCC.

• Authors : REN, WEIGANG¹; LI, JING^2,3,4 ; ZENG, RUIJIANG^3,4

Subjects: *PROGRAMMED death-ligand 1; *IMMUNE response; *RENAL cell carcinoma

• Source: Biocell. 2024, Vol. 48 Issue 9, p1323-1330. 8p.

تفاصيل العنوان

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

• Authors : Biagio Ricciuti, MD, PhD; Arielle Elkrief, MD; Jessica Lin, MD

Subjects: PD-L1; Cemiplimab; Pembrolizumab

• Source: JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100675- (2024)

تفاصيل العنوان

LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer

• Authors : Bo Wu; Xin Huang; Xiang Shi

Subjects: LAMTOR1; Exosomes; PD-L1

• Source: Molecular Cancer, Vol 23, Iss 1, Pp 1-16 (2024)

تفاصيل العنوان

Case report: response to immunotherapy and association with the fh gene in hereditary leiomyomatosis and renal cell cancer-associated renal cell cancer.

• Authors : Gao, Fangfang¹ (AUTHOR); Gu, Dejian² (AUTHOR); Zhang, He³ (AUTHOR)

• Source: BMC Medical Genomics. 8/19/2024, Vol. 17 Issue 1, p1-8. 8p.

تفاصيل العنوان

CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells.

• Authors : Abounar, Summer A.¹ (AUTHOR) ; El-Nikhely, Nefertiti A.^1,2 (AUTHOR) ; Turkowski, Kati³ (AUTHOR)

• Source: International Journal of Molecular Sciences. Aug2024, Vol. 25 Issue 16, p9086. 14p.

تفاصيل العنوان